EGFR and lung cancer: In a preference study involving Japanese patients with EGFR‐positive non‐small cell lung cancer and their doctors, both patients and doctors responded that PFS and overall response rate were the most important factors driving their treatment preferences, whereas annual cost ranked lower in priority than moderate gastrointestinal symptoms and skin‐related symptoms [46].